SGLT2 Inhibitors: Debating Kidney Function Assessment Amid Proven Benefits

An upcoming article questions the perceived kidney benefits of SGLT2 inhibitors, suggesting estimated GFR improvements may be a 'mirage' due to muscle loss and hyperfiltration. However, extensive global research affirms significant long-term renal and cardiovascular protection, especially relevant for India's diabetic population.

• Upcoming article challenges SGLT2 inhibitor kidney benefits interpretation.
• Claims eGFR improvements may be overestimated due to muscle loss, hyperfiltration.
• Overwhelming scientific consensus confirms SGLT2 inhibitors' real kidney protection.
• Drugs significantly reduce kidney failure, cardiovascular risk in CKD patients.
• Relevance to India is high due to diabetes and associated complications.
• Baishideng Publishing Group's credibility has been questioned by external lists.

Read the full story on Quick Digest.